Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance of its US patent application, protecting therapeutic agents based on a novel radiodense analog of its lead therapeutic product PV-10, from the US Patent and Trademark Office.
Subscribe to our email newsletter
The pending patent covers therapeutic agents that are used in conjunction with radiation therapy to improve the efficiency and specificity of radiation for oncology. The agents, called radiosensitizers, are based on a novel molecule related to PV-10, the company’s lead oncology product.
Craig Dees, CEO of Provectus, said: “Like PV-10, these new agents are not radioactive; instead they serve to magnify the cancer-killing effects of radiation therapy by selectively sensitizing cancerous tissue to applied radiation. The hope is that this can serve to dramatically reduce the amount of radiation needed and minimize its effects in normal tissue.”